Studies enrolling at Montrose Clinic. (Clinical Trial Information).

The following studies are enrolling at the Montrose Clinic in Houston. To find out more information, contact Rick Witt at 713.830.3013, extension 521.

* A4311006: Capravirine is an experimental non-nucleoside reverse transcriptase inhibitor ("non-nuke"). This drug may be active against

HIV that is resistant to other non-nukes like Sustiva and Viramune. This study will look at the combination of capravirine and Kaletra in patients who have failed other anti-HIV drugs. To be eligible for the study, you must have HIV that became resistant to at least 1 (but no more than 3) protease inhibitors, 1 non-nuke, and at least 2 nukes (such as Epivir, Ziagen, Zerit, Videx, or Retrovir). Your viral load must be greater than 1000.

* MDX010-10: The antibody MDX010-10 works by binding to the CD4 receptor on T cells and affecting the body's immune response to HIV. Such antibodies may be a new type of anti-HIV therapy for people with HIV, but more research is needed. Patients with drug-resistant HIV (verified by resistance testing) who have gone through 2 prior drug regimens are eligible for this study. T cell count must be greater than or equal to 100, and viral load must be between 1000 and 100,000.